特发性肺动脉高压
Idiopathic pulmonary arterial hypertension
定义
特发性肺动脉高压(IPAH)是一种散发性肺动脉高压(PAH)，其特征与肺动脉阻力升高导致右心衰竭相关。IPAH是进行性的，具有潜在的致命性，与潜在疾病或PAH家族史无关。
别名
原发性肺动脉高压
基本事实
- 遗传方式
- 不适用
- 发病年龄
- 各年龄段
- 患病率
- 1-9 / 1 000 000
临床表型 18
必现 100%1
- 呼吸困难 HP:0002094
极常见 99–80%5
- 颈静脉形态异常 HP:3000042
- 肺动脉压升高 HP:0004890
- 肺血管阻力增加 HP:0005317
- 肺动脉高压 HP:0002092
- 右心室肥厚 HP:0001667
常见 79–30%7
- 踝关节肿胀 HP:0001785
- 胸痛 HP:0100749
- 充血性心力衰竭 HP:0001635
- 足背水肿 HP:0012098
- 心脏杂音 HP:0030148
- 晕厥 HP:0001279
- 三尖瓣反流 HP:0005180
偶见 29–5%3
- 咯血 HP:0002105
- 心悸 HP:0001962
- 下肢水肿 HP:0010741
排除 0%2
- 结缔组织异常 HP:0003549
- 慢性溶血性贫血 HP:0004870
近两年的全球研究 577L2
2024/08 起在 Europe PMC 检索所得，按发表时间倒序显示最近 20 篇。标题未译成中文——自动翻译需要接入 LLM 服务，尚未引入。
- 2026-08病例报告Sheehan Syndrome as a Hidden Cause of Postpartum Clinical Deterioration in Severe Idiopathic Pulmonary Arterial Hypertension
- 2026-07Phenotypic Clustering of Idiopathic Pulmonary Arterial Hypertension: Insights Into Pulmonary Vascular and Cardiometabolic Co-Morbidity Trajectories
- 2026-07随机对照试验Empagliflozin Ameliorates Experimental Pulmonary Vascular Remodeling, but May Not Benefit Patients With Pulmonary Arterial Hypertension
- 2026-07Integrated transcriptomic and machine learning analysis identifies female-associated candidate biomarkers in Idiopathic pulmonary arterial hypertension
- 2026-07Misdiagnosed as Idiopathic PAH: Methylmalonic Acidemia as a Reversible Cause of Pediatric Pulmonary Hypertension
- 2026-07Divergent Inflammatory and Bioenergetic Metabolomic Signatures Distinguish Methamphetamine-Associated From Idiopathic Pulmonary Arterial Hypertension
- 2026-07综述Comparison of Functional and Hemodynamic Parameters Between Methamphetamine-Associated and Idiopathic Pulmonary Arterial Hypertension: Systematic Review and Meta-Analysis
- 2026-07Alterations in the fecal virome and bacteriome-virome interplay in IPAH
- 2026-06综述Pulmonary hypertension following lung transplant: a systematic review
- 2026-06开放获取ANO1 (TMEM16A) Genetic Variants, Promoter Methylation, and Chloride Dysregulation in Pulmonary Hypertension
- 2026-06开放获取Dissection of the pulmonary artery: a rare complication
- 2026-06开放获取Predictive Value of the Pulmonary Artery Pulsatility Index in Pulmonary Arterial Hypertension: REVEAL Analysis
- 2026-05综述开放获取Molecular-Genetic Basis of Pulmonary Arterial Hypertension (PAH)
- 2026-05综述开放获取The Role of Platelets in Pulmonary Hypertension: From Activation to Pulmonary Vascular Remodeling—A Review Article
- 2026-05Characterization of CT Imaging-Derived Pulmonary Vascular Abnormalities Associated With Pulmonary Hypertension in Chronic Lung Disease
- 2026-05Hypoxia Upregulation of BACH1 Aggravates Pulmonary Hypertension Through TGFBR2/SMAD Pathways
- 2026-05综述开放获取O-GlcNAcylation as a Metabolic Integrator in Cardiovascular Physiology and Disease
- 2026-05病例报告开放获取A Rare Case of Multi-System Involvement and Hereditary Pulmonary Hypertension Caused by De Novo Heterozygous <i>CAV1</i> Mutation in a Pediatric Patient
- 2026-05Integrated Single-Cell Atlas Reveals Cross-Subtype Heterogeneity in Human Pulmonary Hypertension
- 2026-05开放获取The Role of the Cellular Communication Network Protein Family in Pulmonary Arterial Hypertension
境外已获批用于本病的药物 23L2
欧盟 10 项、美国 13 项。同一药物在两地各批一次的，会分别列出。
「境外已获批」不等于「在中国能用」。中间隔着进口注册、临床急需境外新药通道、海南博鳌乐城国际医疗旅游先行区等几条路径，各有各的条件与费用。这一节能确定地告诉你的只有一件事：这个病在世界范围内已经有获得批准的药物，它叫什么名字。拿这个名字去问主治医生，是下一步最省力的做法。
药名一律保留英文原文，不作翻译——中国的药品通用名与英文名的音译经常不一致，译错会让人去找一个不存在的药。
- Tracleer欧盟2002-05-14bosentan官方记录
- Revatio欧盟2005-10-28sildenafil官方记录
- Volibris欧盟2008-04-21ambrisentan官方记录
- Adcirca (previously Tadalafil Lilly)欧盟2008-10-01tadalafil官方记录
- Stayveer欧盟2013-06-24bosentan monohydrate官方记录
- Opsumit欧盟2013-12-20macitentan官方记录
- Adempas欧盟2014-03-27riociguat官方记录
- Uptravi欧盟2016-05-12selexipag官方记录
- Winrevair欧盟2024-08-22sotatercept官方记录
- Yuvanci欧盟2024-09-27macitentan;tadalafil官方记录
- Tracleer美国2001-11-20bosentan官方记录
- Remodulin;Orenitram美国2002-05-21treprostinil官方记录
- Ventavis美国2004-12-29Iloprost inhalation solution官方记录
- Letairis美国2007-06-15ambrisentan官方记录
- Adcirca美国2009-05-22tadalafil官方记录
- Tyvaso美国2009-07-30treprostinil inhalation solution官方记录
- Adempas美国2013-10-08riociguat官方记录
- Opsumit美国2013-10-18macitentan官方记录
- Uptravi美国2015-12-21selexipag官方记录
- Tyvaso DPI美国2022-05-23treprostinil inhalation powder官方记录
- Revatio美国2023-01-31sildenafil官方记录
- Opsynvi美国2024-03-22macitentan and tadalafil官方记录
- Winrevair美国2024-03-26sotatercept-csrk官方记录
已获孤儿药资格、尚未获批的在研药物（55 项）
孤儿药资格只是一种监管身份——它意味着监管机构认可这是罕见病用药并给予研发激励，不代表这个药已被证明有效，也不代表将来一定能上市。绝大多数最终不会成药。列在这里是为了看清有哪些方向正在被尝试。
- vasoactive Intestinal Peptide欧盟2003-12-22Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension官方记录
- Tyvaso; Tyvaso欧盟2004-04-14treprostinil sodiumTreatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension官方记录
- Orepaxam欧盟2005-08-26treprostinil diethanolamineTreatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension官方记录
- Elafin欧盟2007-03-20Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension官方记录
- terguride欧盟2007-11-29Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension官方记录
- Lisuride hydrogen maleate欧盟2011-05-13Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension官方记录
- sodium nitrite欧盟2012-03-05Treatment of pulmonary arterial hypertension官方记录
- ubenimex欧盟2016-03-21Treatment of pulmonary arterial hypertension官方记录
- (S)-8-{2-amino-6-[1-(5-chloro-biphenyl-2-yl)-(R)-2,2,2-trifluoro-ethox欧盟2017-04-20Treatment of pulmonary arterial hypertension官方记录
- tacrolimus欧盟2017-08-23Treatment of pulmonary arterial hypertension官方记录
- N-(tert-butylcarbamoyl)-5-cyano-2-((4'-(difluoromethoxy)-[1,1'-bipheny欧盟2018-02-22Treatment of pulmonary arterial hypertension官方记录
- ralinepag欧盟2019-01-11Treatment of pulmonary arterial hypertension官方记录
- (S)-3-((3-(1-((6-(3,4-dimethoxyphenyl)pryazin-2-yl)amino)ethyl)phenyl)欧盟2019-05-29Treatment of pulmonary arterial hypertension官方记录
- imatinib欧盟2021-06-21Treatment of pulmonary arterial hypertension官方记录
- anti-(endothelin-1 receptor subtype A) IgG4 humanised monoclonal antib欧盟2021-12-10Treatment of pulmonary arterial hypertension官方记录
- sodium valproate欧盟2024-08-21Treatment of pulmonary arterial hypertension官方记录
- Sitaxsentan Sodium美国2004-11-02For the treatment of pulmonary arterial hypertension in the absence of chronic obstructive pulmonary disease or congestive heart failure.官方记录
- aviptadil美国2005-02-22Treatment of pulmonary arterial hypertension官方记录
- 2-methoxyestradiol美国2005-04-11Treatment of pulmonary arterial hypertension官方记录
- sodium nitrite美国2008-07-08Treatment of pulmonary arterial hypertension官方记录
- sodium dichloroacetate美国2010-11-29For pulmonary arterial hypertension.官方记录
- iferanserin (S-MPEC)美国2010-12-13For use in pulmonary arterial hypertension.官方记录
- Angiotensin-(1-7)美国2011-09-13Treatment of pulmonary arterial hypertension.官方记录
- nitric oxide美国2011-12-28Treatment of pulmonary arterial hypertension官方记录
- iloprost美国2012-04-06Treatment of pulmonary arterial hypertension官方记录
- tiprelestat美国2012-12-28Treatment of pulmonary arterial hypertension官方记录
- lisuride美国2013-01-17Treatment of pulmonary arterial hypertension官方记录
- vasoactive intestinal peptide (VIP)-elastin-like peptide (ELP) fusion 美国2014-05-13Treatment of pulmonary arterial hypertension, WHO Group 1官方记录
- ralinepag美国2014-08-28treatment of pulmonary arterial hypertension官方记录
- (S)-3-((3-(1-((6-((3,4-dimethoxyphenyl)pryazin-2-yl)amino)ethyl)phenyl美国2014-11-17Treatment of pulmonary arterial hypertension官方记录
- tacrolimus美国2015-03-16Treatment of pulmonary arterial hypertension.官方记录
- bardoxolone美国2015-03-30Treatment of pulmonary arterial hypertension官方记录
- rodatristat ethyl美国2015-10-06Treatment of pulmonary arterial hypertension (PAH).官方记录
- ubenimex美国2015-11-19Treatment of pulmonary arterial hypertension.官方记录
- treprostinil sodium solution enclosed within a pre-filled, pre-program美国2015-12-29Treatment of pulmonary arterial hypertension官方记录
- 6-(4-(4-(2,3-dichlorophenyl)-piperazin-1-yl)-butoxy)-2H-benzo[b][1,4]o美国2016-11-09Treatment of pulmonary arterial hypertension (WHO Group 1)官方记录
- patecibart美国2017-06-06Treatment of pulmonary arterial hypertension (PAH)官方记录
- Active calcium sensing receptor antagonist derived from tetrahydropyra美国2017-06-13Treatment of pulmonary arterial hypertension官方记录
- 2-{4-[(9R)-9-Hydroxy-2-(3-hydroxy-3-methylbutyloxy)-9-(trifluoromethyl美国2018-01-23Treatment of pulmonary arterial hypertension官方记录
- N-(tert-butylcarbamoyl)-5-cyano-2-((4'-(difluoromethoxy)-[1,1'-bipheny美国2018-03-01Treatment of pulmonary arterial hypertension官方记录
另有 15 项未列出。
数据来自欧洲药品管理局（EMA）的药品与孤儿药资格公开导出表，以及美国 FDA 孤儿药资格数据库。两边口径不同：欧盟一侧取的是当前状态仍为「已授权」的药品；美国一侧记录的是「曾获批准」这一事实，FDA 的公开表不追踪药物此后是否退市（例如 Relyvrio 于 2024 年撤市，表中仍记为已获批）。请以官方记录页为准。
在中国开展的临床试验 90L2
按病名在 ClinicalTrials.gov 检索、并校验研究中心含中国大陆而来。登记状态不等于现在真的能入组——务必按 NCT 号到原站核实，并与主治医生商量。
登记为可入组 19
- 招募中NCT02061787the Application of Cardiopulmonary Exercise Testing in Assessment Outcome of Patients With Pulmonary Hypertension中国研究中心 1 个：Beijing
- 招募中NCT07184814Clinical Features and Prognosis of Takayasu's Arteritis With Pulmonary Arteries Involvement中国研究中心 1 个：Beijing
- 招募中NCT06954727China Pulmonary Vascular Disease Intervention Diagnosis and Management Study-right Heart Catheterization中国研究中心 1 个：Beijing
- 仅邀请入组NCT03683186A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension中国研究中心 5 个：Beijing、Changsha、Guangzhou、Shanghai
- 招募中NCT05368467National Registry and Cohort Study of Pulmonary Vascular Disease中国研究中心 13 个：Beijing、Changsha、Chendu、Guangzhou、Nanjing、Shenyang 等 10 地
- 招募中NCT05179876A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option中国研究中心 7 个：Beijing、Changsha、Nanjing、Qingdao、Shanghai、Xi'an
- 招募中NCT05566002Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension中国研究中心 1 个：Beijing
- 招募中NCT06605794FreeFlow Percutaneous Atrial Septal Shunt for IPAH中国研究中心 1 个：Shanghai
- 招募中NCT07604805Efficacy and Safety of Qishen Yiqi Dropping Pills in Patients With Severe Pulmonary Hypertension中国研究中心 1 个：Guangzhou
- 招募中NCT06528418Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath中国研究中心 1 个：Guangzhou
- 招募中NCT07149935Continuous Effect Of Rehabilitation Training On Pulmonary Arterial Hypertension Patients中国研究中心 1 个：Shanghai
- 招募中NCT06554301A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension中国研究中心 1 个：Beijing
- 招募中NCT06753981Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study中国研究中心 1 个：Jinan
- 招募中NCT07039604Real-World Study of PADN for the Treatment of PAH中国研究中心 1 个：Nanjing
- 尚未开始招募NCT06922916Perioperative Risk Factors Related to the Prognosis of Lung Transplantation: A Retrospective Study中国研究中心 1 个：Hangzhou
- 招募中NCT06968962Comparison of Sequential to Initial Combination Therapy in PAH中国研究中心 1 个：Hangzhou
- 招募中NCT07073820A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489中国研究中心 4 个：Changsha、Guangzhou、Nanjing、Shanghai
- 招募中NCT07593027A Phase Ⅰb/Ⅱa Clinical Study of IMC-003 Injection for the Treatment of Pulmonary Arterial Hypertension Receiving Background Therapy.中国研究中心 26 个：Beijing、Changsha、Chengdu、Fuzhou、Guangzhou、Guiyang 等 19 地
- 尚未开始招募NCT07667829Vasopressor Agents in Pulmonary Hypertension Crisis中国研究中心 3 个：Beijing、Guangzhou、Wuhan
其他状态的试验（71 项）
- 已完成NCT00257413Safety and Efficacy Study of Transplantation of EPCs to Treat Idiopathic Pulmonary Arterial Hypertension中国研究中心 1 个：Hangzhou
- 已完成NCT00091715Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II中国研究中心 1 个：Hong Kong
- 已完成NCT00641836Safety and Feasibility of Autologous Endothelial Progenitor Cells Transplantation in Patients With Idiopathic Pulmonary Arterial Hypertension中国研究中心 1 个：Hangzhou
- 已完成NCT00240656Spironolactone Combined With Captopril and Carvedilol for the Treatment of Pulmonary Arterial Hypertension中国研究中心 1 个：Shijiazhuang
- 状态未知NCT00372346Safety and Efficacy Study of Transplantation of EPCs to Treat Idiopathic Pulmonary Arterial Hypertension中国研究中心 1 个：Hangzhou
- 已完成NCT00325403FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)中国研究中心 3 个：Beijing、Shanghai
- 已完成NCT01027949An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension中国研究中心 3 个：Beijing、Shanghai
- 已完成NCT00615823Atorvastatin in Pulmonary Hypertension中国研究中心 1 个：Beijing
- 已终止NCT00430716To Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension.中国研究中心 2 个：Beijing、Shanghai
- 已完成NCT00660179Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension中国研究中心 9 个：Beijing、Guangzhou、Nanjing、Shanghai
- 已完成NCT00718952The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension中国研究中心 9 个：Beijing、Changsha、Harbin、Shanghai、Shenyang、Xi’an
- 已终止NCT00706082Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc)中国研究中心 1 个：Beijing
- 已完成NCT00667823Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension中国研究中心 8 个：Beijing、Guangzhou、Nanjing、Shanghai
- 已终止NCT00795639Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)中国研究中心 4 个：Beijing、Changsha、Shanghai、Xi’an
- 已完成NCT00810693A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)中国研究中心 3 个：Beijing、Guangzhou、Shanghai
- 已完成NCT00863681BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension中国研究中心 3 个：Beijing、Guangzhou、Shanghai
- 已终止NCT00796666Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil中国研究中心 3 个：Beijing、Changsha、Shanghai
- 状态未知NCT01417338Registry for Pulmonary Hypertension in China中国研究中心 1 个：Beijing
- 已完成NCT01106014Selexipag (ACT-293987) in Pulmonary Arterial Hypertension中国研究中心 7 个：Beijing、Guangzhou、Shanghai
- 已完成NCT01112306ACT-293987 in Pulmonary Arterial Hypertension中国研究中心 3 个：Beijing、Guangzhou、Shanghai
- 已完成NCT01338415FUTURE 3 Study Extension中国研究中心 2 个：Beijing、Shanghai
- 已完成NCT01447628IV Iron Replacement for Iron Deficiency in Idiopathic Pulmonary Arterial Hypertension (IPAH) Patients中国研究中心 1 个：Beijing
- 状态未知NCT03567668Surgical Valvuloplasty for Congenital Mitral Insufficiency中国研究中心 1 个：Tianjin
- 已完成NCT01560624Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy中国研究中心 16 个：Beijing、Changsha、Chengdu、Guangzhou、Nanchang、Nanjing 等 10 地
- 状态未知NCT01712997Study of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Hypertension Patients中国研究中心 2 个：Xi'an
- 已完成NCT01808313Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)中国研究中心 8 个：Beijing、Changchun、Harbin、Hunan、Jinan、Shanghai 等 8 地
- 已完成NCT07164157The Risk of Adverse Pregnancy Outcomes for Long-term Exposure to Air Pollution in Pregnant Patients With Pulmonary Hypertension中国研究中心 1 个：Chongqing
- 状态未知NCT01637675Efficacy and Safety Study of Sodium Tanshinone IIA Sulfonate on Pulmonary Hypertension中国研究中心 1 个：Guangzhou
- 已完成NCT01743001Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome中国研究中心 6 个：Beijing、Guangzhou、Shanghai、Shenyang、Wuhan
- 已终止NCT01739400Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome中国研究中心 6 个：Beijing、Guangzhou、Shanghai、Shenyang、Wuhan
- 已完成NCT01560637An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension中国研究中心 16 个：Beijing、Changsha、Chengdu、Guangzhou、Nanchang、Nanjing 等 10 地
- 状态未知NCT02023450Testing of HIV Protease Inhibitors to Suppress Inflammation and Improve Cardio Pulmonary Hemodynamics in Subjects With Pulmonary Arterial Hypertension中国研究中心 1 个：Changsha
- 已完成NCT02267200The Screening and Analysis of Plasma Biomarkers in Irreversible PAH-CHD中国研究中心 1 个：Shanghai
- 已终止NCT02284737A Study to Investigate the Efficacy of PADN to Improved Functional Capacity and Hemodynamics in Patients With PAH中国研究中心 1 个：Nanjing
- 已撤回NCT02893995Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension中国研究中心 10 个：Beijing、Changsha、Guangzhou、Shanghai、Wuhan
- 已撤回NCT02882126An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension中国研究中心 10 个：Beijing、Changsha、Guangzhou、Shanghai、Wuhan
- 已完成NCT02932410A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)中国研究中心 4 个：Beijing、Qingdao、Shanghai
- 状态未知NCT04053296Long-term Outcomes of Pregnant Women With PAH中国研究中心 1 个：Shanghai
- 状态未知NCT03954405Multi-marker Approach for Risk Assessment in PAH中国研究中心 1 个：Wuhan
- 已完成NCT03282266Safety and Efficacy of Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension中国研究中心 1 个：Nanjing
另有 31 项未列出。
中国境外的在招试验 132L2
这些试验在中国没有研究中心，通常无法直接报名——入组一般要求在当地居住并接受随访。列在这里是因为它另有用处：看清楚全世界正在试哪些药、做到了哪一期、由谁在做。把药名和 NCT 编号记下来去问主治医生，或据此进一步查该药是否已在境外获批、是否有拓展性用药（expanded access）通道。
美国45法国14西班牙10巴西10英国10德国8加拿大7澳大利亚7意大利7比利时6波兰6以色列4拉脱维亚4韩国4另有 29 个国家/地区
CT.gov 报告命中 132 项，此处取回并展示最近的 15 项。
- 尚未开始招募NCT07172334What is the Role of the Exposome in Pulmonary Hypertension法国
- 尚未开始招募NCT07600723A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037)
- 尚未开始招募NCT07632898Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)
- 尚未开始招募NCT07737522Myocardial Metabolic Flux in Pulmonary Arterial Hypertension
- 尚未开始招募NCT07700303Withdrawal of Prostacyclin Pathway Therapy in Patients With Pulmonary Arterial Hypertension Receiving Sotatercept (WATERLOO)加拿大
- 尚未开始招募NCT07761572CS1 Added to Standard of Care Therapy for Pulmonary Arterial Hypertension
- 尚未开始招募NCT07717060Extracellular Vesicle Dynamics Predicting Vascular Complications and Treatment Response in Systemic Sclerosis
- 尚未开始招募NCT06176118Clinical Trial of 2-HOBA in Pulmonary Arterial Hypertension
- 尚未开始招募NCT07751120Microbiota Transplant With Antibiotic Preconditioning and Fiber Supplementation in PAH.美国
- 尚未开始招募NCT07759804A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag美国
- 尚未开始招募NCT07646860A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032)
- 招募中NCT07613099Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging美国
- 招募中NCT07143448A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults西班牙、美国
- 招募中NCT07713914Randomized Study of Triple Therapy vs Sildenafil Dose Optimization in Pulmonary Arterial Hypertension巴西
- 尚未开始招募NCT07357974Impact of Sotatercept on Pulmonary Artery and Right Ventricle Remodeling Imaging Assessed With 68Ga-FAPI PET/CT in Patients With PAH法国
外部标识与链接
发现这一页有错误？告诉我 · 邮件主题会自动带上本页的 ORPHA 编号
本页数据来源
- 疾病定义、同义词、基因、表型、流行病学：Orphanet（CC BY 4.0）
- 中文病名：Orphanet 中文包，冻结于 2020-06-01
- 表型中文标签：HPO 简体中文翻译（CHPO 上游成果）